Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Fate Therapeutics (NASDAQ:FATE) but has reduced the price target from $5 to $3.
November 13, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Fate Therapeutics but lowered the price target from $5 to $3, indicating a potential downside based on the analyst's view.
The reduction in price target by a major analyst like Morgan Stanley suggests a bearish outlook on the stock's value, which could lead to a negative short-term impact on the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100